Fennec Pharmaceuticals (FENC) to Release Quarterly Earnings on Thursday

Fennec Pharmaceuticals (NASDAQ:FENC) is scheduled to be announcing its earnings results before the market opens on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.

Fennec Pharmaceuticals (NASDAQ:FENC) last announced its earnings results on Tuesday, August 13th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.26). Fennec Pharmaceuticals had a net margin of 5.59% and a negative return on equity of 53.38%. The company had revenue of $7.26 million for the quarter, compared to analyst estimates of $13.67 million. During the same quarter last year, the company posted ($0.21) EPS. On average, analysts expect Fennec Pharmaceuticals to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Fennec Pharmaceuticals Price Performance

Shares of NASDAQ FENC traded up $0.14 during trading on Tuesday, reaching $4.79. The company had a trading volume of 56,024 shares, compared to its average volume of 112,186. The company has a current ratio of 8.02, a quick ratio of 7.75 and a debt-to-equity ratio of 9.86. Fennec Pharmaceuticals has a twelve month low of $4.09 and a twelve month high of $11.92. The stock has a 50-day moving average price of $4.92 and a two-hundred day moving average price of $6.23. The stock has a market capitalization of $131.35 million, a PE ratio of 122.50 and a beta of 0.27.

Analyst Ratings Changes

A number of research analysts have issued reports on FENC shares. HC Wainwright reduced their target price on shares of Fennec Pharmaceuticals from $15.00 to $13.00 and set a “buy” rating on the stock in a report on Thursday, August 22nd. Wedbush restated an “outperform” rating and set a $14.00 target price (down previously from $16.00) on shares of Fennec Pharmaceuticals in a research report on Tuesday, August 13th. Finally, Craig Hallum cut their price target on Fennec Pharmaceuticals from $17.00 to $15.00 and set a “buy” rating for the company in a report on Wednesday, August 14th.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.